ClinicalTrials.gov record
Completed Phase 2 Interventional

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

ClinicalTrials.gov ID: NCT05262270

Public ClinicalTrials.gov record NCT05262270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Placebo-Controlled Trial of Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

Study identification

NCT ID
NCT05262270
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
University of Texas Southwestern Medical Center
Other
Enrollment
427 participants

Conditions and interventions

Interventions

  • Extended Release Buprenorphine Drug
  • Extended-Release Naltrexone Drug
  • Placebo (PLB) Injectable matched to XR-BUP Drug
  • Placebo (PLB) Injectable matched to XR-NTX Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 17, 2023
Primary completion
Jun 26, 2025
Completion
Jul 20, 2025
Last update posted
Oct 20, 2025

2023 – 2025

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35209
University of Arkansas for Medical Sciences Little Rock Arkansas 72205
UCLA Vine Street Clinic Los Angeles California 90038
Center on Substance Use and Health (CSUH) San Francisco California 94102
Cove Behavioral Health Tampa Florida 33605
University of Illinois at Chicago Chicago Illinois 60608
University of Chicago Chicago Illinois 60637
Mountain Manor Treatment Center Baltimore Maryland 21229
Berman Center for Outcomes and Clinical Research at Hennepin Healthcare Minneapolis Minnesota 55404
Addictions Institute of Mount Sinai New York New York 10029
UTSW Medical Center, Center for Depression Research and Clinical Care Dallas Texas 75247
University of Texas Health San Antonio San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05262270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 20, 2025 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05262270 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →